| 抗结核药物的研究与开发 |
| |
| 引用本文： | 陈国良,谭国良,孙平华.抗结核药物的研究与开发[J].药学进展,2004,28(12):529-537. |
| |
| 作者姓名： | 陈国良 谭国良 孙平华 |
| |
| 作者单位： | 1. 沈阳药科大学制药工程学院,辽宁,沈阳,110016
2. 暨南大学药学院,广东,广州,510632 |
| |
| 摘 要： | 近年来结核病重新在全球肆虐，艾滋病加速了结核病的流行，对多种药物具有耐药性的结核杆菌的蔓延，迫切需要研制新的抗结核病新药。综述近二十多年来喹诺酮类、硝基咪唑类、利福霉素衍生物、氨基糖苷类、噁唑烷酮类等13类抗结核病药物的研究与开发。
|
| 关 键 词： | 抗结核病药物 结核分支杆菌 抑制活性 作用机制 |
| 文章编号： | 1001-5094(2004)12-0529-09 |
| 修稿时间： | 2004年6月10日 |
Research and Development of Anti-tuberculosis Drugs |
| |
| CHEN Guo-liang,TAN Guo-liang,SUN Ping-hua.Research and Development of Anti-tuberculosis Drugs[J].Progress in Pharmaceutical Sciences,2004,28(12):529-537. |
| |
| Authors: | CHEN Guo-liang TAN Guo-liang SUN Ping-hua |
| |
| Abstract: | In recent years, tuberculosis has been resurrected around the world. AIDS is increasing its incidence greatly. And multidrug-resistant tuberculosis often occurs. So new anti-tuberculosis drugs are urgently required. Recent advances in thirteen categories of anti-tuberculosis drugs, including quinolones, nitroimid-azoles, rifamycins, aminoglycosides, oxazolidinones and so on, were reviewed. |
| |
| Keywords: | Anti-tuberculosis drug Mycobacterium tuberculosis Inhibiting activity Acting mechanism |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
